原发性骨髓纤维化:2019年诊断、风险分层与管理更新
本文综述原发性骨髓纤维化(PMF)的诊断、风险分层与治疗。诊断基于骨髓形态,JAK2、CALR或MPL突变支持但不必需。新预后系统GIPSS和MIPSS70+ version 2.0分别含4个和5个风险类别,指导风险适配治疗:低/极低危观察,高/极高危优选异基因移植,中危参加临床试验。
要点
- 诊断基于骨髓形态,JAK2、CALR或MPL突变约见于90%患者,支持但不必需诊断。
- GIPSS仅基于突变和核型,MIPSS70+ version 2.0结合遗传与临床因素,后者需在线计算器。
- 低/极低危观察,高/极高危优选异基因移植,中危参加临床试验;其他治疗多为姑息。
核心结论
- PMF诊断基于骨髓形态,2016年WHO分类区分prefibrotic与overtly fibrotic PMF,前者表现可类似ET且预后相关。
- GIPSS和MIPSS70+ version 2.0为新预后系统,分别含4个和5个风险类别。
- 风险适配治疗:低/极低危观察,高/极高危优选异基因移植,中危参加临床试验;其他治疗多为姑息。
研究设计与样本
- 综述,基于2019年更新的PMF诊断、风险分层和管理文献。
主要发现
- JAK2、CALR或MPL突变约见于90%的PMF患者,支持但不必需诊断。
- MIPSS70+ version 2.0低和极低危估计10年生存率56%-92%,高和极高危0-13%,中危30%。
关键数值与推荐
- GIPSS基于突变和核型,含4个风险类别;MIPSS70+ version 2.0结合遗传和临床因素,含5个风险类别,需在线计算器(http://www.mipss70score.it)。
- 观察适用于MIPSS70+ version 2.0低和极低危(估计10年生存率56%-92%);异基因干细胞移植为高和极高危首选(估计10年生存率0-13%);中危(估计10年生存率30%)最好参加临床试验。
- 贫血常规治疗包括雄激素、泼尼松、沙利度胺和达那唑;症状性脾肿大用羟基脲和芦可替尼;体质性症状用芦可替尼。
- 药物难治性脾肿大考虑脾切除,非肝脾EMH和肢体骨痛考虑累及野放疗。
临床怎么用
- 低/极低危PMF可仅观察;高/极高危优选异基因干细胞移植;中危参加临床试验。
- JAK2抑制剂等治疗多为姑息,无明确治疗指征时不应使用。
- 贫血用雄激素、泼尼松、沙利度胺或达那唑;症状性脾肿大用羟基脲或芦可替尼;体质性症状用芦可替尼。
- 药物难治性脾肿大考虑脾切除;非肝脾EMH和肢体骨痛考虑累及野放疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional disease features include bone marrow stromal reaction including reticulin fibrosis, abnormal cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. DIAGNOSIS: Diagnosis of PMF is based on bone marrow morphology. Presence of JAK2, CALR, or MPL mutation, expected in ∼ 90% of the patients, is supportive but not essential for diagnosis. The revised 2016 World Health Organization (WHO) classification system distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former might mimic ET in its presentation and it is prognostically relevant to distinguish the two. RISK STRATIFICATION: Two new prognostic systems for PMF have recently been introduced: GIPSS (genetically inspired prognostic scoring system) and MIPSS70+ version 2.0 (mutation- and karyotype-enhanced international prognostic scoring system). GIPSS is based exclusively on mutations and karyotype. MIPSS70+ version 2.0 utilizes both genetic and clinical risk factors. GIPSS features four and MIPSS70+ version 2.0 five risk categories. MIPSS70+ version 2.0 requires an online score calculator (http://www.mipss70score.it) while GIPPS offers a lower complexity prognostic tool. RISK-ADAPTED THERAPY: Observation alone is advised for MIPSS70+ version 2.0 "low" and "very low" risk disease (estimated 10-year survival 56%-92%); allogeneic stem cell transplant is the preferred treatment of choice for "very high" and "high" risk disease (estimated 10-year survival 0-13%); treatment-requiring patients with intermediate-risk disease (estimated 10-year survival 30%) are best served by participating in clinical trials. All other treatment approaches, including the use of JAK2 inhibitors, are mostly palliative and should not be used in the absence of clear treatment indications. Conventional treatment for anemia includes androgens, prednisone, thalidomide and danazol, for symptomatic splenomegaly hydroxyurea and ruxolitinib and for constitutional symptoms ruxolitinib. Splenectomy is considered for drug-refractory splenomegaly and involved field radiotherapy for nonhepatosplenic EMH and extremity bone pain.
引用
- Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018. PMID: 30039550. doi:10.1002/ajh.25230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。